Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Key Points

• The study aims to evaluate the effectiveness of immunosuppressive therapy in young children with acquired severe aplastic anemia.
• Collaborative study design involving multiple North American centers.
• Focus on children under 3 years of age with severe aplastic anemia.
• Assessment of treatment response rates to immunosuppressive therapy.
• High response rates observed in children under 3 receiving immunosuppressive therapy for severe aplastic anemia.
• Successful differentiation between acquired severe aplastic anemia and inherited syndromes in younger patients.